⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCGN News
Ocugen, Inc. Common Stock
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
OCGN
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
globenewswire.com
OCGN
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
globenewswire.com
OCGN
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
globenewswire.com
OCGN
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
globenewswire.com
OCGN
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
globenewswire.com
OCGN
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
globenewswire.com
OCGN
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
globenewswire.com
OCGN
Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence
prnewswire.com
EDIT
NTLA
RPTX
NVS
GILD
BMY
VRTX
CRL
OCGN
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
globenewswire.com
OCGN